Overview
Status
Active
Registry date
2019-02-18
Share capital
5,000.00 PLN
Registered address
ul. Wilcza 3/58, 00-538 Warszawa, Poland
Website
Email
Electronic delivery address
AE:PL-76317-26910-FJCDJ-22
Financials
Revenue history (in k)
Filing timeliness
4 of 6 financial statements were filed late (the longest delay 210 days for 2021).
- 202519/10/2026
- 202415/07/2025
- 202319/08/2024
- 202220/12/2023
- 202110/02/2023
- 202002/08/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 53.65kMedianUSD 1.06mAverageUSD 22.40m
Net profit
This companyUSD -59.92kMedianUSD 37.33kAverageUSD 880.24k
Operating costs
This companyUSD 111.91kMedianUSD 922.77kAverageUSD 21.08m
Assets
This companyUSD 49.74kMedianUSD 608.93kAverageUSD 11.85m
Industry
Authorized Representatives
Małgorzata Daniela Grotowska – Management Board Member
Tadeusz Zbigniew Grotowski – Management Board Member & Attorney-in-fact (sole)
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Bartosz Kiljańskiage 40 | 50 | $675.31 | 50% |
Marta Legierskaage 56 | 50 | $675.31 | 50% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2019-02-27.
Debt
1 closed proceeding recorded in KRZ history.
| Registration date | Proceeding type | Status | |
|---|---|---|---|
| Aug 6, 2025 | Petition to declare entrepreneur bankruptcy | Closed |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 18, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | –– | Prezydent Miasta Stołecznego Warszawy | |
| May 7, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | –– | TRZECI US WARSZAWA - ŚRÓDMIEŚCIE |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Asmedi Internationalsp. z o.o. | $408,113.21 | asmediinternational.com | ||
| Swiss-Labsp. z o.o. | $394,867.25 | swisslab.pl | ||
| Beauty Care Solutionsp. z o.o. | $391,209.94 | ohhira.pl | ||
| Medcellsp. z o.o. | $339,369.93 | medcell.pl | ||
| GSH Polskasp. z o.o. | $313,619.12 | gshpolska.pl | ||
| Pro-Medicasp. z o.o. | $243,649.02 | promedica.com.pl | ||
| Aimedicalsp. z o.o. | $240,059.72 | aimedical.pl | ||
| Vorwarts Pharmasp. z o.o. | $210,138.62 | vorwartspharma.pl | ||
| Mudii Dystrybucjasp. z o.o. | $197,492.47 | mudii.com | ||
| Mitramed Paweł Wysocki, Piotr Wachaczyksp. j. | $198,282.96 | e.pl |
FAQ
The main business activity of Medifides focuses on wholesale of pharmaceutical goods.
The company was registered in the Polish National Court Register (KRS) on February 18, 2019.
The headquarters is located at: ul. Wilcza 3, 00-538 Warszawa.
The management board consists of: Małgorzata Daniela Grotowska (Member of the Management Board) and Tadeusz Zbigniew Grotowski (Member of the Management Board).
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
The company reported a revenue of USD 53,649 in 2025, which is a decrease of 80.2% compared to 2024.
No, in 2025 the company was not profitable, reporting a net loss of USD 59,919. For comparison, in 2024 the loss was USD 33,303, meaning the company increased its loss by 79.5%.
The largest operating cost category falls under cost of goods and materials sold. This category amounted to USD 95,907 in 2025, representing 86% of all operating expenses.
Last updated: 2026-10-19
